Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) EPS (Weighted Average and Diluted) (2019 - 2025)

Assembly Biosciences (ASMB) has 7 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.53 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 64.9% year-over-year to -$0.53; the TTM value through Sep 2025 reached -$4.6, up 33.53%, while the annual FY2024 figure was -$6.69, 50.0% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.53 in Q3 2025 per ASMB's latest filing, up from -$1.33 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.27 in Q3 2023 and bottomed at -$21.62 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$2.33, with a median of -$1.25 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 1478.1% in 2022, then surged 91.81% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.37 in 2021, then plummeted by 1478.1% to -$21.62 in 2022, then skyrocketed by 91.81% to -$1.77 in 2023, then grew by 11.3% to -$1.57 in 2024, then skyrocketed by 66.24% to -$0.53 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.53 in Q3 2025, -$1.33 in Q2 2025, and -$1.17 in Q1 2025.